glp 1 for weight loss uk GLP-1 Agonists Drugs Market Size & Outlook, 2030 The GLP-1 Solution: A Complete

While we continue to see Novo Nordisk as a wide-moat firm, with strong intangible assets surrounding its cardiometabolic business, we think the high obesity drug demand and scarcity of supply have driven share prices above their intrinsic value

Compound: Melanotan II (Melanocortin Analog)

A multicenter study involving 304 LADY patients (primarily from Germany and Australia) showed that 75.9% received insulin therapy, initiated on average 1.1 years after diagnosis, with the average dose gradually increasing from 0.5 IE/kg at start to 0.8 IE/kg at follow-up (71)

Srinivasans team shared its findings in the December 2023 Science Advances